Allogeneic transplantation for Hodgkin's lymphoma.

摘要: Hodgkin's lymphoma (HL) can be cured in most of the patients, but case refractory disease or relapse after autologous stem cell transplantation (SCT) prognosis becomes very poor. In these patients a consensus about standard approach has not been achieved so far and only allogeneic SCT shown long-term control. The postulated graft-versus-Hodgkin's is matter controversy, clinical responses observed donor lymphocyte infusions may explain superiority alloSCT over chemo-radiotherapy. results conventional myeloablative had relevant non-relapse mortality (NRM), discouraging its widespread application as salvage treatment. last 10 years, reduced intensity conditioning (RIC) significantly decreased NRM, widening also to heavily pretreated patients. Taking into account all phase II studies, 20-30% receiving RIC are disease-free probably some them cured.